All In Biotech

Drug Trial Radar · NCT06252649

Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb for Treatment-naïve Subjects With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (CodeBreaK 301)

Last checked: Nov 19, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 450 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

450

Planned (sponsor's estimate)

Start

Jul 17, 2024

Primary completion

Sep 25, 2028

Study completion Apr 25, 2032

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Feb 12, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this study is to compare progression free survival (PFS) in treatment-naïve participants with KRAS p.G12C mutated metastatic colorectal cancer (mCRC) receiving sotorasib, panitumumab and FOLFIRI vs FOLFIRI with or without bevacizumab-awwb.

Conditions

  • Metastatic Colorectal Cancer

Interventions

  • FOLFIRI RegimenDrug

    Combination of irinotecan, leucovorin, and 5-fluorouracil given via IV infusion Q2W.

  • SotorasibDrug

    Immediate-release solid dosage form administered orally.

  • PanitumumabDrug

    Administered via IV infusion Q2W.

  • Bevacizumab-awwbDrug

    Administered via IV infusion Q2W.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PFS per Response Evaluation Criteria in Solid Tumors (RECIST v1.1)Time frame: Up to Approximately 3 Years

Locations

291 sites in 35 countries. Site status is shown where the registry gives one.

  • Ironwood Cancer and Research Centers Scottsdale

    Chandler, Arizona · Recruiting

  • Providence Saint Jude Medical Center

    Fullerton, California · Terminated

  • City of Hope National Medical Center

    Long Beach, California · Recruiting

  • Cancer and Blood Research Center, LLC

    Los Alamitos, California · Recruiting

  • California Research Institute

    Los Angeles, California · Terminated

  • Norwalk Hospital

    Norwalk, Connecticut · Terminated

  • Cancer Specialists of North Florida - Southpoint

    Jacksonville, Florida · Recruiting

  • D and H Cancer Research Center

    Margate, Florida · Terminated

  • Mid Florida Hematology and Oncology Centers PA

    Orange City, Florida · Terminated

  • Boca Raton Clinical Research Medical Center Inc

    Plantation, Florida · Terminated

  • Georgia Cancer Specialists

    Atlanta, Georgia · Terminated

  • Insight Research Institute

    Chicago, Illinois · Recruiting

  • Hope and Healing Cancer Services

    Hinsdale, Illinois · Terminated

  • Orchard Healthcare Research Inc

    Skokie, Illinois · Terminated

  • Pikeville Medical Center

    Pikeville, Kentucky · Recruiting

  • Henry Ford Health System

    Detroit, Michigan · Terminated

  • Cancer and Hematology Centers of Western Michigan

    Grand Rapids, Michigan · Recruiting

  • Saint Louis Cancer Care West County

    Bridgeton, Missouri · Terminated

  • Minniti Center for Medical Oncology and Hematology

    Mickleton, New Jersey · Terminated

  • Duke Cancer Center

    Durham, North Carolina · Recruiting

  • FirstHealth Cancer Center

    Pinehurst, North Carolina · Terminated

  • Thomas Jefferson University

    Philadelphia, Pennsylvania · Terminated

  • Carolina Blood and Cancer Care

    Rock Hill, South Carolina · Terminated

  • Tennessee Oncology PLLC - Chattanooga

    Nashville, Tennessee · Recruiting

  • Tennessee Oncology, PLLC

    Nashville, Tennessee · Recruiting

  • Vanderbilt University Medical Center

    Nashville, Tennessee · Recruiting

  • Hospital Britanico de Buenos Aires

    Buenos Aires, Argentina · Recruiting

  • Centro Oncologico Riojano Integral

    La Rioja, Argentina · Terminated

  • Hospital Universitario Fundacion Favaloro

    CABA, Buenos Aires, Argentina · Recruiting

  • Instituto Argentino de Diagnóstico y Tratamiento

    CABA, Buenos Aires, Argentina · Recruiting

  • Investigaciones Clinicas Moleculares - Centro de Endocrinologia y Diabetes Dr Raul Gutman SRL

    CABA, Buenos Aires, Argentina · Recruiting

  • Cemic

    Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina · Terminated

  • Sanatorio Británico de Rosario

    La Plata, Buenos Aires, Argentina · Recruiting

  • Instituto de Investigaciones clinicas de Mar del Plata

    Mar del Plata, Buenos Aires, Argentina · Recruiting

  • Hospital Italiano de Córdoba

    Córdoba, Córdoba Province, Argentina · Recruiting

  • Sanatorio Allende

    Córdoba, Córdoba Province, Argentina · Terminated

  • Clinica Universitaria Privada Reina Fabiola

    Córdoba, Córdoba Province, Argentina · Recruiting

  • Clinica Viedma

    Viedma, Río Negro Province, Argentina · Recruiting

  • Exelsus Oncologia Clinica

    San Miguel de Tucumán, Tucumán Province, Argentina · Recruiting

  • Chris OBrien Lifehouse

    Camperdown, New South Wales, Australia · Recruiting

Showing 40 of 291 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.